Literature DB >> 16785987

Fusion tyrosine kinases: a result and cause of genomic instability.

E T P Penserga1, T Skorski.   

Abstract

Reciprocal chromosomal translocations may arise as a result of unfaithful repair of spontaneous DNA double-strand breaks, most probably induced by oxidative stress, radiation, genotoxic chemicals and/or replication stress. Genes encoding tyrosine kinases are targeted by these mechanisms resulting in the generation of chimera genes encoding fusion tyrosine kinases (FTKs). FTKs display transforming activity owing to their constitutive kinase activity causing deregulated proliferation, apoptosis, differentiation and adhesion. Moreover, FTKs are able to facilitate DNA repair, prolong activation of G(2)/M and S cell cycle checkpoints, and elevate expression of antiapoptotic protein Bcl-X(L), making malignant cells less responsive to antitumor treatment. FTKs may also stimulate the generation of reactive oxygen species and enhance spontaneous DNA damage in tumor cells. Unfortunately, FTKs compromise the fidelity of DNA repair mechanisms, which contribute to the accumulation of additional genetic abnormalities leading to the resistance to inhibitors such as imatinib mesylate and malignant progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785987     DOI: 10.1038/sj.onc.1209756

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia.

Authors:  Susanne M Gollin
Journal:  Semin Cancer Biol       Date:  2006-10-26       Impact factor: 15.707

2.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

3.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

4.  Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.

Authors:  Jee Hyun Kong; Yeung-Chul Mun; Seonwoo Kim; Hang Seok Choi; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Joon Ho Moon; Sang Kyun Sohn; Sung-Hyun Kim; Chul Won Jung; Dong Hwan Dennis Kim
Journal:  Int J Hematol       Date:  2012-07-21       Impact factor: 2.490

5.  Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Authors:  Don L Gibbons; Sabrina Pricl; Paola Posocco; Erik Laurini; Maurizio Fermeglia; Hanshi Sun; Moshe Talpaz; Nicholas Donato; Alfonso Quintás-Cardama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

6.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

7.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

8.  BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

Authors:  Margret S Fernandes; Mamatha M Reddy; Jeffrey R Gonneville; Scott C DeRoo; Klaus Podar; James D Griffin; David M Weinstock; Martin Sattler
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

9.  Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.

Authors:  Manabu Kurokawa; Chen Zhao; Tannishtha Reya; Sally Kornbluth
Journal:  Mol Cell Biol       Date:  2008-06-30       Impact factor: 4.272

10.  Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells.

Authors:  Yin Gao; Adrienne Howard; Kechen Ban; Joya Chandra
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.